HBM Healthcare Investments Aktie
WKN: 984345 / ISIN: CH0012627250
03.04.2023 17:53:04
|
HBM Healthcare Investments publishes net asset value per share of CHF 254.80 as at 31 March 2023
HBM Healthcare Investments AG / Key word(s): Personnel HBM Healthcare Investments closed the fourth quarter of the 2022/2023 financial year ended on 31 March with a small increase in value. The net asset value per share (NAV) increased by 0.5 percent to CHF 254.80. The share price rose by 6.5 percent to CHF 214.00. High level of cash and cash equivalents allows continuation of cash distribution policy For the 2022/2023 financial year, the NAV decreased by 7.4 per cent. The private companies (incl. funds) recorded a positive development overall and increased the NAV by 1.6 percent. The listed companies and the other components of the portfolio (incl. costs) reduced the net asset value by 7.7 and 1.3 percent respectively. Based on the reported NAV as at 31 March, HBM Healthcare Investments expects a net loss of CHF 146 million for the financial year 2022/2023. The balanced portfolio and the high level of cash and cash equivalents of CHF 232 million allow for the repayment of the CHF 50 million bond due in July from cash on hand as well as the continuation of the company's investment activities and distribution policy. The figures presented are the preliminary and unaudited results based on the current status of the closing process. The final annual result will be published on Friday, 12 May 2023. Contact End of Inside Information |
Language: | English |
Company: | HBM Healthcare Investments AG |
Bundesplatz 1 | |
6300 Zug | |
Switzerland | |
Phone: | +41438887171 |
Fax: | +41438887172 |
E-mail: | info@hbmhealthcare.com |
Internet: | https://www.hbmhealthcare.com |
ISIN: | CH0012627250 |
Valor: | 1262725 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1600123 |
End of Announcement | EQS News Service |
|
1600123 03-Apr-2023 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu HBM Healthcare Investments AGmehr Nachrichten
16.04.25 |
Key Figures 15.04.2025 (EQS Group) | |
01.04.25 |
HBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year (EQS Group) | |
01.04.25 |
HBM Healthcare Investments erwartet Jahresgewinn von CHF 19 Millionen für das Geschäftsjahr 2024/2025 (EQS Group) | |
01.04.25 |
Key Figures 31.03.2025 (EQS Group) | |
20.03.25 |
Sanofi erwirbt DR-0201, ein klinisches Programm des HBM-Portfolio-Unternehmens Dren Bio, für einen Vorabbetrag von USD 600 Millionen, zuzüglich möglicher Meilensteine (EQS Group) | |
20.03.25 |
Sanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestones (EQS Group) | |
17.03.25 |
Key Figures 15.03.2025 (EQS Group) | |
03.03.25 |
Key Figures 28.02.2025 (EQS Group) |
Analysen zu HBM Healthcare Investments AGmehr Analysen
Aktien in diesem Artikel
HBM Healthcare Investments AG | 164,00 | 0,61% |
|